{Reference Type}: Case Reports
{Title}: Paraneoplastic Sensory Polyneuropathy Related to Anti-PD-L1-including Anticancer Treatment in a Patient with Lung Cancer.
{Author}: Morimoto T;Orihashi T;Yamasaki K;Tahara M;Kato K;Yatera K;
{Journal}: Intern Med
{Volume}: 60
{Issue}: 10
{Year}: May 2021 15
{Factor}: 1.282
{DOI}: 10.2169/internalmedicine.5629-20
{Abstract}: Paraneoplastic neurological syndromes (PNS), such as sensory polyneuropathy, are rare, and serum neuronal antibodies that are used for diagnosing this syndrome are occasionally positive. Similarly, neurological immune-related adverse events due to immune checkpoint inhibitors (ICIs) are also rare. However, their etiologies and the relationship between them remain unclear. We herein report a patient with suspected small cell lung cancer who showed sensory polyneuropathy after treatment with atezolizumab in combination with cytotoxic agents (carboplatin and etoposide) and was doubly positive for serum anti-Hu and anti-SOX-1 antibodies. Treatment with ICI and cytotoxic agents may sometimes lead to the development of PNS.